Dare I mention the words..., page-24

The more NEU de-risks approval of trofintide, higher the $$ Big Pharma will be willing to fork out, so from NEU’s perspective a deal done after Phase 3 of Retts and NDA application of trof probably suits best to get max $$. (Same scenario was played out at ACR, so RT is in tune with this strategy and I can’t see a reason not to continue the same winning formula).
Having said that, there is nothing stopping a Big pharma to come with an outstanding $$ offer prior which NEU might be tempted to take (but I feel this is less likely prior to results from paediatric trial)
Gut feel is a min of $1 post and a max of $4 post deal